The autonomic nervous system is the crucial link between the brain and the cardiovascular system. It is the final common pathway by which central disturbances whether initiated by exogenous psychological or physical stress, or endogenous biochemical or structural perturbation are translated into alterations in cardiac and vascular function. There is compelling evidence that disordered autonomic engagement of the heart and vasculature contributes importantly to many forms of cardiovascular disease: arrhythmias, sudden death, hypertension, syncope, myocardial infarction, and stoke. The goal of the Program is to achieve better understanding of how the brain exerts control over the autonomic nervous system and how the latter expresses that control onto effector tissues, through the integrating theme of autonomic cardiovascular regulation. The rationale for the Program is the tightly coordinated testing of hypotheses addressing autonomic modulation of cardiovascular function in health and disease. Component projects address central and peripheral autonomic mechanisms, employing both integrated and reductionist approaches. The roles of specific gene products (the norepinephrine transporter), and afferent (baroreflex), efferent (pure autonomic failure and multiple system failure) endocrine (hypoglycemia, exercise) and vascular (nitric oxide) mechanisms are examined. The programmatic approach will facilitate the bidirectional transfer of information between the laboratory and the clinic because it brings together investigators with a wide range of skills who have a track record of discovering new fundamental knowledge and applying it to the creation of practical improvement in health. The Program should lead directly to improved therapy in cardiovascular disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL056693-07
Application #
6610976
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Velletri, Paul A
Project Start
1997-09-20
Project End
2007-07-31
Budget Start
2003-08-01
Budget End
2004-07-31
Support Year
7
Fiscal Year
2003
Total Cost
$1,856,319
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Mar, Philip L; Raj, Satish R (2018) Orthostatic hypotension for the cardiologist. Curr Opin Cardiol 33:66-72
Chaugai, Sandip; Dickson, Alyson L; Shuey, Megan M et al. (2018) Co-Prescription of Strong CYP1A2 Inhibitors and the Risk of Tizanidine-Associated Hypotension: A Retrospective Cohort Study. Clin Pharmacol Ther :
van den Berg, Maarten P; Almomani, Rowida; Biaggioni, Italo et al. (2018) Mutations in CYB561 Causing a Novel Orthostatic Hypotension Syndrome. Circ Res 122:846-854
Mai, Tu H; Garland, Emily M; Diedrich, André et al. (2017) Hepatic and renal mechanisms underlying the osmopressor response. Auton Neurosci 203:58-66
Kawai, V K; Levinson, R T; Adefurin, A et al. (2017) A genetic risk score that includes common type 2 diabetes risk variants is associated with gestational diabetes. Clin Endocrinol (Oxf) 87:149-155
Pezawas, Thomas; Diedrich, André; Robertson, David et al. (2017) Risk of arrhythmic death in ischemic heart disease: a prospective, controlled, observer-blind risk stratification over 10 years. Eur J Clin Invest 47:231-240
Adefurin, A; Ghimire, L V; Kohli, U et al. (2017) Genetic variation in the alpha1B-adrenergic receptor and vascular response. Pharmacogenomics J 17:366-371
Kaufman, Melissa R; Chang-Kit, Laura; Raj, Satish R et al. (2017) Overactive bladder and autonomic dysfunction: Lower urinary tract symptoms in females with postural tachycardia syndrome. Neurourol Urodyn 36:610-613
Shaw, Brett H; Garland, Emily M; Black, Bonnie K et al. (2017) Optimal diagnostic thresholds for diagnosis of orthostatic hypotension with a 'sit-to-stand test'. J Hypertens 35:1019-1025
Kawai, Vivian K; Levinson, Rebecca T; Adefurin, Abiodun et al. (2017) Variation in the ?2A-adrenergic receptor gene and risk of gestational diabetes. Pharmacogenomics 18:1381-1386

Showing the most recent 10 out of 315 publications